Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention
American Heart Journal, ISSN: 0002-8703, Vol: 155, Issue: 6, Page: 1081-1089
2008
- 113Citations
- 30Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations113
- Citation Indexes110
- 110
- CrossRef74
- Policy Citations2
- Policy Citation2
- Clinical Citations1
- PubMed Guidelines1
- Captures30
- Readers30
- 30
Article Description
Drug-eluting stents reduce the risk of restenosis after percutaneous coronary intervention (PCI) but may pose a risk of thrombosis. Cilostazol, an oral antiplatelet agent with pleiotropic effects including inhibition of neointimal hyperplasia, could hold the promise of preventing both restenosis and thrombosis. We systematically reviewed randomized clinical trials (RCTs) on the angiographic and clinical impact of cilostazol after PCI.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0002870308000033; http://dx.doi.org/10.1016/j.ahj.2007.12.024; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=44349138210&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/18513523; https://linkinghub.elsevier.com/retrieve/pii/S0002870308000033; https://dx.doi.org/10.1016/j.ahj.2007.12.024
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know